Vascular Inflammation Stratified by Body Size Phenotype

* Vascular Inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis. 18FDG-PET is a promising novel tool for identifying and quantifying vascular inflammation within atherosclerotic plaque * Recently, unique subsets of obese individuals, such as metabolically obese but normal weight (MONW) and metabolically healthy obese (MHO), have been getting an attention * Therefore, the purpose of this study is to examine the relationship of vascular inflammation,measured by FDG-PET, with various body sized phenotypes

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atherosclerosis Arterial Occlusive Diseases Arteriosclerosis Body Weight Cardiovascular Diseases Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Metabolic Syndrome Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms Vascular Diseases

Age range

20 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Korea University Guro Hospital

Seoul, South Korea

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy patients for visiting routine medical check in our clinic

Exclusion criteria

history of CVD (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)
stage 2 hypertension (resting blood pressure, ≥160/100 mmHg)
history of inflammatory conditions that affect the study results
taking medications that might affect inflammatory status, including steroid and non-steroidal anti-inflammatory drug within 6 months
or malignancy or severe renal or hepatic disease

Treatment and study plan

Primary outcomes

max TBR values stratified by the four body size phenotypes

Time frame: 12 weeks

Secondary outcomes

Framingham risk scores according to the four body size phenotypes

Time frame: 12 weeks

Sponsors and collaborators

Lead sponsor

Korea University

Other

Registry information

Important dates

Study start: 2008
Primary completion: 2011
First posted: Nov 8, 2013
Registry last updated: Nov 8, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed